Pd clinical trials

Explore recruiting pd clinical trials.

Recruiting pd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizuma Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B

Spain, France, Greece, Poland, Italy, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A parallel-group low-intervention, phase IV, randomized, double-blind, placebo-controlled, single-center, national, two-arm trial to investigate efficacy and safety of Cardiodoron® in patients with functional cardiovascular disorders (FCD)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)

Denmark, France, Ireland, Czechia, Poland, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D

Hungary, Poland, Greece, Spain, Italy, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pd trials by city

Pd in Toronto Pd in Vancouver Pd in Montreal Pd in Calgary Pd in Edmonton Pd in Ottawa Pd in Winnipeg Pd in Quebec City Pd in Hamilton Pd in Kitchener Pd in London Pd in Halifax Pd in New York Pd in Los Angeles Pd in Chicago Pd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease